secondary hyperparathyroidism
Conditions
Interventions
Oral calcitol group:Oral calcitol
I.v. Paricalcitol group:I.v. Paricalcitol
Sponsors
The First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. CKD stage 5 and maintenance dialysis for at least 3 months, 3 times a week, Kt/V > 1.2; 2. Initial treatment: Never received active VD and analogues; 3. Treated patients: were receiving active VD and analogues and iPTH levels continued to be higher than 300pg/ml, or showed a continuous upward trend in the past 3 tests; 4. Aged over 18 years; 5. Baseline blood calcium was less than 10.0mg/dL(2.5mmol/L).
Exclusion criteria
Exclusion criteria: 1.The patient's serum iPTH level continued to exceed 1500pg/ml on two consecutive tests recently; 2.The patient had an allergic reaction to active VD and its analogues; 3.Patients who underwent parathyroidectomy within 1 year; 4.Patients meeting the indications for parathyroidectomy; 5.SHPT is severe and the patient is resistant to active VD and its analogues; 6.Persistent hypercalcium and/or hyperphosphatemia that fails to respond to medical treatment; 7.There is at least one radiographic evidence of an enlarged parathyroid gland, such as an enlarged parathyroid gland with a diameter of > 1cm and abundant blood flow on high-frequency color ultrasound; 8.Severe infection; 9.Concomitant malignant tumor; 10.Patients with a history of alcohol or drug abuse in the past 6 months; 11.Pregnancy; 12.Complicated with severe liver disease or liver insufficiency; 13.Allergy or intolerance to any therapeutic drug; 14.Patients were still participating in other drug/device clinical studies 4 weeks prior to enrollment; 15.The inestigators considered the patients unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inflammatory factor levels;Hemoglobin level; | — |
Secondary
| Measure | Time frame |
|---|---|
| Biochemical indicators related to secondary hyperparathyroidism (PTH, Ca, P, and alkaline phosphatase levels and their changes from baseline);Valve calcification;Life Function Scale; | — |
Countries
China
Contacts
Public ContactLu Chen
The First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed